Merck reveals study success, and possible safety worries, for eye drug hopeful

AI Summary

Merck announced positive results from the first pivotal study of a new drug for diabetic macular edema acquired in a $1.3 billion buyout. However, concerns about the drug's safety led to debate among financial analysts.

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.